Status:
COMPLETED
Therapy Protocol Acute Lymphoblastic Leukemia Stem Cell Transplantation International
Lead Sponsor:
Hadassah Medical Organization
Conditions:
Acute Lymphoblastic Leukemia
Eligibility:
All Genders
Up to 18 years
Phase:
NA
Brief Summary
To evaluate whether HSCT from matched family or unrelated donors (MD) is equivalent to the HSCT from matched sibling donors (MSD). To evaluate the efficacy of HSCT from mismatched family or unrelated ...
Eligibility Criteria
Inclusion
- all patients with ALL (except for patients with B-ALL) who fulfil the following criteria:
- age at time of initial diagnosis or relapse diagnosis, respectively
- ≤18 years
- indication for allogeneic HSCT
- complete remission (CR) is achieved before SCT
- written consent of the parents (legal guardian) and, if indicated, the minor patient via "Informed Consent Form"
- no pregnancy
- no secondary malignancy
- no previous HSCT
- HSCT is performed in a study participating centre.
Exclusion
- not signed inform consent of the parents (legal guardian)
- pregnancy
- secondary malignancy
- previous HSCT
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2014
Estimated Enrollment :
552 Patients enrolled
Trial Details
Trial ID
NCT00861679
Start Date
January 1 2007
End Date
September 1 2014
Last Update
March 29 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Schneider Children's Medical Center of Israel
Petach Tikvah, Israel, 49202